Abstract
85 Inefficiency of traditional methods of treatment of cancer patients forces the search of new approaches. Nowadays immunotherapy is considered as such a way and its sufficiency has been proved [1, 2]. Recently new types of immunotherapy have been investigated. Modern international standards of tumor immunotherapy consist of: – multimodal approaches, which make simultaneous influence on different parts of immune system; – usage of polyvalent antigen, that includes wide spectrum of tumor-associated antigens; – reducing of impact or eliminating of factors which supress the immune response, in particular , the number and functional activity of T-regulatory (T-reg) lymphocytes [3,4]. One of such new approaches is chemoimmune therapy (CIT), which implies the usage of low doses of chemical preparations and antitumor immunotherapy, in particular, antitumor vaccine on the base of dendritic cells (DC) [5, 6]. Nowadays the mechanisms of CIT influence on the cancer patients and on the tumor itself are not completely investigated.The standard protocols concerning CIT usage during the treatment of cancer patients are not elaborated. It was established that low doses of chemical preparations make essential influence on tumor microenvironment due to their antiangiogenic effect, particularly thanks their cytotoxic effect on proliferating endotheliocytes of tumor vessels [17]. It was also shown that the usage of above mentioned low doses leads to the decrease of T-reg population with phenotype CD4CD25Fox P3. These lymphocytes possess immunosupressor ability which may enhance antitumor effect of the vaccine [9]. Hence, the elaborating of efficient scheme of CIT is a focal problem of modern oncology. The aim of this investigation was to elaborate the scheme of combine CIT on the base of DCvaccine and low doses of cisplatin in experiment and to study both: the influence of this vaccine on the growth of transplantable tumor and the state of immune system of tumor-bearing mice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
